ALK重排非小细胞肺癌免疫治疗的现状与挑战

Current status and challenges of immunotherapy in ALK rearranged NSCLC.

作者信息

Qi Rongbin, Yu Yingying, Shen Mo, Lv Dongqing, He Susu

机构信息

Department of Respiratory Medicine, TaiZhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.

The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.

出版信息

Front Oncol. 2022 Dec 14;12:1016869. doi: 10.3389/fonc.2022.1016869. eCollection 2022.

DOI:10.3389/fonc.2022.1016869

PMID:36591504

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9795041/

Abstract

Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase inhibitors (TKIs) but prone to drug resistance. Meanwhile, ALK rearranged NSCLC has poor response to single immunotherapy. Here we mainly describe the immune escape mechanisms of ALK mutated NSCLC and the role of related biomarkers. Additionally, we collate and evaluate preclinical and clinical studies of novel immune combination regimens, and describe the prospects and perspectives for the application of novel immune technologies in patients with ALK rearranged NSCLC.

摘要

间变性淋巴瘤激酶（ALK）基因重排在非小细胞肺癌（NSCLC）中占5%-6%。ALK重排的NSCLC对ALK酪氨酸激酶抑制剂（TKIs）敏感，但容易产生耐药性。同时，ALK重排的NSCLC对单一免疫疗法反应不佳。在此，我们主要描述ALK突变的NSCLC的免疫逃逸机制及相关生物标志物的作用。此外，我们整理并评估了新型免疫联合方案的临床前和临床研究，并描述了新型免疫技术在ALK重排的NSCLC患者中应用的前景。